Peter A. Thompson - Jun 4, 2021 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jun 4, 2021
Transactions value $
$0
Form type
4
Date filed
9/21/2021, 05:14 PM
Previous filing
Jun 9, 2021
Next filing
Jun 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +15K $0.00 15K Jun 4, 2021 Common Stock 15K $28.83 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors.
F2 The Reporting Person is the designated representative of OrbiMed Advisors LLC ("OrbiMed Advisors") on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.